scholarly journals Dermatologic Manifestations of Endocrine Disorders

Cureus ◽  
2021 ◽  
Author(s):  
Rishi Raj ◽  
Ghada Elshimy ◽  
Rahul Mishra ◽  
Nivedita Jha ◽  
Vismaya Joseph ◽  
...  
2017 ◽  
Vol 6 (4) ◽  
pp. 300-312 ◽  
Author(s):  
Michael Lause ◽  
Alisha Kamboj ◽  
Esteban Fernandez Faith

2012 ◽  
Vol 24 (4) ◽  
pp. 487-493 ◽  
Author(s):  
Nicola A. Quatrano ◽  
Karen J. Loechner

2018 ◽  
Vol 2 (5) ◽  
pp. 9-14
Author(s):  
Лилия Беленькая ◽  
Liliya Belenkaya ◽  
Олег Иванов ◽  
Oleg Ivanov ◽  
Ольга Панарина ◽  
...  

Background. Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting 5–10 % of reproductive-aged women. The dermatologic manifestations of PCOS play a significant role in diagnosis. The purpose of the present study was to examine the impact of androgenic alopecia among patients with PCOS and to define their most significant trichological features. Because the data on dermatologic changes associated with PCOS are rather scarce, the present study was designed to determine the incidence and prevalence of androgenic alopecia. Materials and methods. We conducted a prospective observational study of patients with PCOS. The diagnosis of PCOS was made according to the consensus criteria adopted in May 2003 in Rotterdam. Each patient signed informed consent, and then a general physical examination, systemic examination, breast and pelvic examination, as well as a detailed trichological examination were carried out. Results. Twenty women with PCOS participated in the study. The median age was 28.7 ± 6.2 years. Oligo/anovulation frequency was 63.2 %, hirsutism frequency – 68.4 %. In our study, the prevalence of androgenic alopecia was found to be 30 %, telogenic hair loss – 55 %, absence of alopecia signs in 15 % of cases. Conclusions. Androgenic alopecia is a prevalent but unreliable marker of biochemical hyperandrogenism. It is therefore imperative for the treating physicians to understand the adverse effects associated with PCOS, recognize these potential health risks in patients, and treat them accordingly.


2002 ◽  
Vol 41 (02) ◽  
pp. 80-90 ◽  
Author(s):  
F. Jockenhövel ◽  
P. Theissen ◽  
M. Dietlein ◽  
W. Krone ◽  
H. Schicha ◽  
...  

SummaryThe following article reviews nuclear medicine techniques which can be used for assessment of endocrine disorders of the hypothalamic-pituitary axis. For planar and SPECT imaging somatostatin-receptor- and dopamine- D2-receptor-scintigraphy are the most widely distributed techniques. These nuclear medicine techniques may be indicated in selected cases to answer differential diagnostic problems. They can be helpful to search for presence and localization of receptor positive tissue. Furthermore they can detect metastasis in the rare cases of a pituitary carcinoma. Scintigraphy with Gallium-67 is suitable for further diagnostic evaluation in suspected hypophysitis. Other SPECT radiopharmaca do not have relevant clinical significance. F-18-FDG as PET radiopharmacon is not ideal because obvious pituitary adenomas could not be visualized. Other PET radiopharmaca including C-11-methionine, C-11-tyrosine, F-18-fluoroethylspiperone, C-11-methylspiperone, and C-11-raclopride are available in specialized centers only. Overall indications for nuclear medicine in studies for the assessment of endocrine disorders of the hypothalamic-pituitary-axis are rare. Original studies often report only about a small number of patients. According to the authors’ opinion the relevance of nuclear medicine in studies of clinically important endocrinologic fields, e. g. localization of small ACTH-producing pituitary adenomas, tumor localization in ectopic ACTH syndrome, localization of recurrent pituitary tissue, assessment of small incidentalomas, can not be definitely given yet.


1955 ◽  
Vol 18 (4) ◽  
pp. 557-559 ◽  
Author(s):  
Henning Andersen ◽  
Gustav Asboe-Hansen ◽  
Flemming Quaade ◽  
Robert Wichmann

1966 ◽  
Vol 51 (1) ◽  
pp. 63-70 ◽  
Author(s):  
P. F. Roe ◽  
D. M. Mitchell ◽  
G. W. Pennington

ABSTRACT Adrenocortical function was assessed in 20 patients receiving long-term corticosteroid drugs for a variety of non-endocrine disorders. In all cases plasma 17-hydroxycorticosteroids (17-OHCS) levels were within or above normal limits 48 hours after abruptly stopping their drugs and a further marked rise occurred in 7 patients given metyrapone for 24 h. Urinary 17-OHCS excretion did not show a parallel rise. Taking the group as a whole, a small rise in the mean output occurred 48 hours after stopping therapy, and a further slightly greater rise followed metyrapone. 3 patients had a relapse of their underlying condition during the test in spite of normal plasma and urinary 17-OHCS levels.


2014 ◽  
Author(s):  
Ekaterina Pigarova ◽  
Larisa Dzeranova ◽  
Liudmila Rozhinskaya ◽  
Alexander Il'in ◽  
Galina Melnichenko

2017 ◽  
Author(s):  
Nikolaos Kalogeris ◽  
Markella Nezi ◽  
Maria Chini ◽  
Athina Lioni ◽  
Vissaria Sakka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document